tiprankstipranks

Austar Lifesciences Reports Positive Turnaround in 2024 Annual Results

Story Highlights
Austar Lifesciences Reports Positive Turnaround in 2024 Annual Results

Don’t Miss TipRanks’ Half-Year Sale

Austar Lifesciences Ltd. ( (HK:6118) ) has issued an announcement.

Austar Lifesciences Ltd. announced its annual results for the year ended December 31, 2024, reporting a turnaround with a profit of RMB 13.6 million from continuing operations, compared to a loss in the previous year. The company’s revenue decreased to RMB 1.5 billion, but improvements in gross profit margin and reductions in selling, marketing, and administrative expenses contributed to the positive outcome. This financial performance indicates a strategic recovery, potentially enhancing the company’s market position and offering positive implications for stakeholders.

More about Austar Lifesciences Ltd.

Austar Lifesciences Ltd. operates in the life sciences industry, focusing on providing solutions and products related to pharmaceuticals and biotechnology. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.

YTD Price Performance: 49.12%

Average Trading Volume: 140,019

Technical Sentiment Signal: Buy

Current Market Cap: HK$435.7M

See more insights into 6118 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1